Safety and Efficacy of Benzalkonium Chloride-optimized Tafluprost in Japanese Glaucoma Patients with Existing Superficial Punctate Keratitis

Katsuyoshi Suzuki, Shinichiro Teranishi, Takeshi Sagara, Hideaki Yoshino, Masako Nakayama, Miho Enoki, Yoshihisa Nuno, Shinji Hirano, Makiko Wakuta, Norihisa Takahashi, Kayoko Tokuhisa, Yukiko Kondo, Rie Shiraishi, Yasuhito Ishida, Kohei Sonoda

研究成果: ジャーナルへの寄稿記事

9 引用 (Scopus)

抄録

Purpose: To evaluate the safety and efficacy of benzalkonium chloride (BAK)-optimized tafluprost (with a BAK concentration reduced from 0.01% to 0.001%) in glaucoma patients with existing superficial punctate keratitis (SPK). Patients and Methods: A prospective, multicenter, open-label study was designed to compare BAK-optimized tafluprost administered over 12 weeks relative to other preserved prostaglandin analogs previously administered in Japanese glaucoma patients. Thirty patients with SPK graded at <6 points by area density (AD) scoring in 1 eye were recruited. The primary outcome measure was change in AD score at 12 weeks after the switch in treatment compared with that at baseline. Secondary outcome measures included changes in tear film breakup time (TBUT), hyperemia score, and intraocular pressure (IOP). Four patients were excluded from analysis because of treatment discontinuation. Results: Mean AD score±SD decreased significantly from 3.4±0.9 to 1.8±1.8 after the switch (P<0.0001). Mean TBUT increased significantly from 6.3±3.3 to 8.0±4.2 seconds (P<0.01). Mean hyperemia score remained unchanged, whereas mean IOP decreased significantly from 15.6±2.6 to 14.4±2.0 mm Hg (P<0.01). For patients previously treated with BAK-preserved latanoprost (n=17) or bimatoprost (n=2), mean AD score decreased significantly from 3.4±0.9 to 1.8±1.8 (P<0.01) and mean TBUT increased significantly from 6.4±3.6 to 8.2±4.3 seconds (P<0.01); no such changes were apparent for patients previously treated with sofZia-preserved travoprost (n=7). Conclusions: BAK-optimized tafluprost is a treatment option to improve the condition of the ocular surface and to maintain IOP control in glaucoma patients with existing SPK who have been previously treated with other BAK-preserved prostaglandin analogs.

元の言語英語
ページ(範囲)e145-e150
ジャーナルJournal of Glaucoma
24
発行部数6
DOI
出版物ステータス出版済み - 8 19 2015
外部発表Yes

Fingerprint

Benzalkonium Compounds
Keratitis
Glaucoma
Safety
Tears
Intraocular Pressure
Synthetic Prostaglandins
latanoprost
Hyperemia
Outcome Assessment (Health Care)
tafluprost
Therapeutics

All Science Journal Classification (ASJC) codes

  • Ophthalmology

これを引用

Safety and Efficacy of Benzalkonium Chloride-optimized Tafluprost in Japanese Glaucoma Patients with Existing Superficial Punctate Keratitis. / Suzuki, Katsuyoshi; Teranishi, Shinichiro; Sagara, Takeshi; Yoshino, Hideaki; Nakayama, Masako; Enoki, Miho; Nuno, Yoshihisa; Hirano, Shinji; Wakuta, Makiko; Takahashi, Norihisa; Tokuhisa, Kayoko; Kondo, Yukiko; Shiraishi, Rie; Ishida, Yasuhito; Sonoda, Kohei.

:: Journal of Glaucoma, 巻 24, 番号 6, 19.08.2015, p. e145-e150.

研究成果: ジャーナルへの寄稿記事

Suzuki, K, Teranishi, S, Sagara, T, Yoshino, H, Nakayama, M, Enoki, M, Nuno, Y, Hirano, S, Wakuta, M, Takahashi, N, Tokuhisa, K, Kondo, Y, Shiraishi, R, Ishida, Y & Sonoda, K 2015, 'Safety and Efficacy of Benzalkonium Chloride-optimized Tafluprost in Japanese Glaucoma Patients with Existing Superficial Punctate Keratitis', Journal of Glaucoma, 巻. 24, 番号 6, pp. e145-e150. https://doi.org/10.1097/IJG.0000000000000020
Suzuki, Katsuyoshi ; Teranishi, Shinichiro ; Sagara, Takeshi ; Yoshino, Hideaki ; Nakayama, Masako ; Enoki, Miho ; Nuno, Yoshihisa ; Hirano, Shinji ; Wakuta, Makiko ; Takahashi, Norihisa ; Tokuhisa, Kayoko ; Kondo, Yukiko ; Shiraishi, Rie ; Ishida, Yasuhito ; Sonoda, Kohei. / Safety and Efficacy of Benzalkonium Chloride-optimized Tafluprost in Japanese Glaucoma Patients with Existing Superficial Punctate Keratitis. :: Journal of Glaucoma. 2015 ; 巻 24, 番号 6. pp. e145-e150.
@article{3bf33737f7bd42189c20f504b991d55d,
title = "Safety and Efficacy of Benzalkonium Chloride-optimized Tafluprost in Japanese Glaucoma Patients with Existing Superficial Punctate Keratitis",
abstract = "Purpose: To evaluate the safety and efficacy of benzalkonium chloride (BAK)-optimized tafluprost (with a BAK concentration reduced from 0.01{\%} to 0.001{\%}) in glaucoma patients with existing superficial punctate keratitis (SPK). Patients and Methods: A prospective, multicenter, open-label study was designed to compare BAK-optimized tafluprost administered over 12 weeks relative to other preserved prostaglandin analogs previously administered in Japanese glaucoma patients. Thirty patients with SPK graded at <6 points by area density (AD) scoring in 1 eye were recruited. The primary outcome measure was change in AD score at 12 weeks after the switch in treatment compared with that at baseline. Secondary outcome measures included changes in tear film breakup time (TBUT), hyperemia score, and intraocular pressure (IOP). Four patients were excluded from analysis because of treatment discontinuation. Results: Mean AD score±SD decreased significantly from 3.4±0.9 to 1.8±1.8 after the switch (P<0.0001). Mean TBUT increased significantly from 6.3±3.3 to 8.0±4.2 seconds (P<0.01). Mean hyperemia score remained unchanged, whereas mean IOP decreased significantly from 15.6±2.6 to 14.4±2.0 mm Hg (P<0.01). For patients previously treated with BAK-preserved latanoprost (n=17) or bimatoprost (n=2), mean AD score decreased significantly from 3.4±0.9 to 1.8±1.8 (P<0.01) and mean TBUT increased significantly from 6.4±3.6 to 8.2±4.3 seconds (P<0.01); no such changes were apparent for patients previously treated with sofZia-preserved travoprost (n=7). Conclusions: BAK-optimized tafluprost is a treatment option to improve the condition of the ocular surface and to maintain IOP control in glaucoma patients with existing SPK who have been previously treated with other BAK-preserved prostaglandin analogs.",
author = "Katsuyoshi Suzuki and Shinichiro Teranishi and Takeshi Sagara and Hideaki Yoshino and Masako Nakayama and Miho Enoki and Yoshihisa Nuno and Shinji Hirano and Makiko Wakuta and Norihisa Takahashi and Kayoko Tokuhisa and Yukiko Kondo and Rie Shiraishi and Yasuhito Ishida and Kohei Sonoda",
year = "2015",
month = "8",
day = "19",
doi = "10.1097/IJG.0000000000000020",
language = "English",
volume = "24",
pages = "e145--e150",
journal = "Journal of Glaucoma",
issn = "1057-0829",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Safety and Efficacy of Benzalkonium Chloride-optimized Tafluprost in Japanese Glaucoma Patients with Existing Superficial Punctate Keratitis

AU - Suzuki, Katsuyoshi

AU - Teranishi, Shinichiro

AU - Sagara, Takeshi

AU - Yoshino, Hideaki

AU - Nakayama, Masako

AU - Enoki, Miho

AU - Nuno, Yoshihisa

AU - Hirano, Shinji

AU - Wakuta, Makiko

AU - Takahashi, Norihisa

AU - Tokuhisa, Kayoko

AU - Kondo, Yukiko

AU - Shiraishi, Rie

AU - Ishida, Yasuhito

AU - Sonoda, Kohei

PY - 2015/8/19

Y1 - 2015/8/19

N2 - Purpose: To evaluate the safety and efficacy of benzalkonium chloride (BAK)-optimized tafluprost (with a BAK concentration reduced from 0.01% to 0.001%) in glaucoma patients with existing superficial punctate keratitis (SPK). Patients and Methods: A prospective, multicenter, open-label study was designed to compare BAK-optimized tafluprost administered over 12 weeks relative to other preserved prostaglandin analogs previously administered in Japanese glaucoma patients. Thirty patients with SPK graded at <6 points by area density (AD) scoring in 1 eye were recruited. The primary outcome measure was change in AD score at 12 weeks after the switch in treatment compared with that at baseline. Secondary outcome measures included changes in tear film breakup time (TBUT), hyperemia score, and intraocular pressure (IOP). Four patients were excluded from analysis because of treatment discontinuation. Results: Mean AD score±SD decreased significantly from 3.4±0.9 to 1.8±1.8 after the switch (P<0.0001). Mean TBUT increased significantly from 6.3±3.3 to 8.0±4.2 seconds (P<0.01). Mean hyperemia score remained unchanged, whereas mean IOP decreased significantly from 15.6±2.6 to 14.4±2.0 mm Hg (P<0.01). For patients previously treated with BAK-preserved latanoprost (n=17) or bimatoprost (n=2), mean AD score decreased significantly from 3.4±0.9 to 1.8±1.8 (P<0.01) and mean TBUT increased significantly from 6.4±3.6 to 8.2±4.3 seconds (P<0.01); no such changes were apparent for patients previously treated with sofZia-preserved travoprost (n=7). Conclusions: BAK-optimized tafluprost is a treatment option to improve the condition of the ocular surface and to maintain IOP control in glaucoma patients with existing SPK who have been previously treated with other BAK-preserved prostaglandin analogs.

AB - Purpose: To evaluate the safety and efficacy of benzalkonium chloride (BAK)-optimized tafluprost (with a BAK concentration reduced from 0.01% to 0.001%) in glaucoma patients with existing superficial punctate keratitis (SPK). Patients and Methods: A prospective, multicenter, open-label study was designed to compare BAK-optimized tafluprost administered over 12 weeks relative to other preserved prostaglandin analogs previously administered in Japanese glaucoma patients. Thirty patients with SPK graded at <6 points by area density (AD) scoring in 1 eye were recruited. The primary outcome measure was change in AD score at 12 weeks after the switch in treatment compared with that at baseline. Secondary outcome measures included changes in tear film breakup time (TBUT), hyperemia score, and intraocular pressure (IOP). Four patients were excluded from analysis because of treatment discontinuation. Results: Mean AD score±SD decreased significantly from 3.4±0.9 to 1.8±1.8 after the switch (P<0.0001). Mean TBUT increased significantly from 6.3±3.3 to 8.0±4.2 seconds (P<0.01). Mean hyperemia score remained unchanged, whereas mean IOP decreased significantly from 15.6±2.6 to 14.4±2.0 mm Hg (P<0.01). For patients previously treated with BAK-preserved latanoprost (n=17) or bimatoprost (n=2), mean AD score decreased significantly from 3.4±0.9 to 1.8±1.8 (P<0.01) and mean TBUT increased significantly from 6.4±3.6 to 8.2±4.3 seconds (P<0.01); no such changes were apparent for patients previously treated with sofZia-preserved travoprost (n=7). Conclusions: BAK-optimized tafluprost is a treatment option to improve the condition of the ocular surface and to maintain IOP control in glaucoma patients with existing SPK who have been previously treated with other BAK-preserved prostaglandin analogs.

UR - http://www.scopus.com/inward/record.url?scp=84939569923&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84939569923&partnerID=8YFLogxK

U2 - 10.1097/IJG.0000000000000020

DO - 10.1097/IJG.0000000000000020

M3 - Article

VL - 24

SP - e145-e150

JO - Journal of Glaucoma

JF - Journal of Glaucoma

SN - 1057-0829

IS - 6

ER -